FTO is reported to induce the expression of immune checkpoint leukocyte immunoglobulin-like receptor subfamily B 4 (LILRB4), which contributes to T cell suppression and tumor infiltration in AML, leading to immune evasion (115).Upon treatment with decitabine, FTO expression was significantly increased, resulting in decreased m6A abundance in AML cells. The gene discussed is FTO; the disease is neoplasm.